SOURCE: EyeGate Pharma

April 11, 2007 08:05 ET

EyeGate Pharma to Present at IBC's International Conference on Ocular Anti-Angiogenesis

'Ocular Drug Delivery: An Alternative to a Poke in the Eye'

WALTHAM, MA -- (MARKET WIRE) -- April 11, 2007 -- EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that Gary P. Cook, Ph.D., Senior Director, Chemistry and Drug Delivery, will make a podium presentation at IBC's 4th International Conference on Ocular Anti-Angiogenesis. Dr. Cook's presentation, titled "Ocular Drug Delivery: An Alternative to a Poke in the Eye," will take place on Monday, April 16, 2007 at 4:15 PM, at the Royal Sonesta Hotel Boston in Cambridge, MA.

During his presentation, Dr. Cook will detail the EyeGate® II Delivery System, a novel platform-technology that represents a safe, noninvasive and well-tolerated alternative to today's invasive and/or ineffective ocular drug delivery modalities. Dr. Cook will also discuss how EyeGate's iontophoresis technology can effectively deliver efficacious doses of a wide range of therapeutic molecules to the front and back of the eye, passing both the conjunctiva and blood-retina barriers and depositing in ocular tissue.

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This noninvasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies using the EyeGate® II Delivery System are planned for 2008.

Contact Information

  • IR/PR Contact:
    Bryan Murphy
    LaVoie Group
    (978) 745-4200 X105
    Email Contact